TY - JOUR T1 - JAK2 Specificity and Thrombosis Risk: Potential Role of Antiphospholipid Antibodies JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.180722 SP - jrheum.180722 AU - Bruce M. Rothschild Y1 - 2018/11/15 UR - http://www.jrheum.org/content/early/2018/11/12/jrheum.180722.abstract N2 - Janus kinase (JAK) inhibitors are a relatively new addition to our tools for treatment of rheumatoid arthritis (RA)1. They are responsible for transduction of more than 38 cytokinases2, with diffuse metabolic/immunologic implications. ER -